Finally, did the nicotine addiction fulfill your party?
Smoking is one of the most harmful habits to adopt because it can cause lung cancer, heart disease and several other health problems. However, more than 22% of the world population uses tobacco, according to the World Health Organization, with more than 8 million people who die annually.
About half of adult smokers try to quit each year, but usually less than 10% are successful, mainly due to problems that manage intense desires and withdrawal symptoms.
The United States Food and Medicine Administration has approved two medications designed to help reduce tobacco wishes: Bupropion (Markets and Wowbutrin) and Varenicline (Chantix).
Now, Korea scientists have found that Parkinson Prociclidin’s disease disease can relieve the physical symptoms of nicotine withdrawal, such as tremors and a decrease in mobility.
“This study has new possibilities for the treatment of smoking to mitigating the interruptions caused by the symptoms of withdrawal,” said Heh-in from the Cerebral Disorders Center of the Institute of Science and Technology in Korea. “Provides an additional treatment option next to Bupropion and Varenicline.”
Parkinson’s patients have an imbalance between acetylcholine neurotransmitters and dopamine within striatus, a part of the brain deeply involved in movement and processing control rewards.
Dopamine exhaustion is the main cause of Parkinson’s engine symptoms.
Procicylidine works to restore balance by blocking the activity of colinergic interneurons, nerve cells that release acetylcholine. The drug deals with muscle stiffness, tremors and spasms in Parkinson’s patients.
The IM group found that giving a single low dose of procylidine to mice with symptoms of nicotine withdrawal reduced the tremors by more than 50%.
The idea is that nicotine is structurally similar to acetylcholine, which allows it to join the receptors of the colinergic interneurons. Team experiments showed that the abolition of interneurons restored dopamine levels to striat.
Dopamine is known as the “felt” hormone and cigarette nicotine stimulates its release. Quitters often experience desires because they miss the dopamine coup. The restoration of dopamine would facilitate removal.
“Advant, we want to deepen the understanding of the mechanisms of addiction, including nicotine and develop effective therapies,” said IM.
The results of the IM study were published in November in Advanced Science Magazine.
Since procylidine is already approved in the United States and other countries, the next step is to make sure that it does not interact with the treatments established to smoke and see if the punch can help people quit for the better.
#amazing #scientists #smokers #alleviate #removal #nicotine
Image Source : nypost.com